


### VIMPAT® Share of Total U.S. AED Dollar Sales 2009 – February 2015



Source: Ex. 2176, p. 2 (IMS)

—■— VIMPAT® Share Among Branded AEDs    —◆— VIMPAT® Share Among All AEDs

**VIMPAT® U.S. Dollar Sales and Share of Total AED Dollar Sales**  
**2009 – February 2015**

	2009	2010	2011	2012	2013	2014	Jan-Feb 2015	
IMS Estimated Sales (\$MM)								
VIMPAT®	\$35.5	\$135.8	\$227.5	\$338.6	\$475.2	\$629.0	\$114.9	[1]
Branded AEDs	\$1,766.9	\$1,462.4	\$1,514.4	\$1,592.9	\$1,732.2	\$2,025.7	\$360.8	[2]
All AEDs	\$2,354.2	\$1,991.5	\$2,043.9	\$2,074.6	\$2,396.2	\$2,769.6	\$482.4	[3]
VIMPAT® Share								
Among Branded AEDs	2.0%	9.3%	15.0%	21.3%	27.4%	31.1%	31.9%	[4]
Among All AEDs	1.5%	6.8%	11.1%	16.3%	19.8%	22.7%	23.8%	[5]

**Notes:**

I understand from counsel that UCB's standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.

VIMPAT® launched May 2009.

**Sources:**

[1], [2], [3]: Ex. 2176, p. 4 (IMS)

[4] = [1] / [2]

[5] = [1] / [3]

## AED Shares of Total U.S. Branded Sales Dollars Associated with Epilepsy Indications 2009 – February 2015

AED	2009	2010	2011	2012	2013	2014	Jan-Feb 2015
APTIOM						0.7%	1.7%
BANZEL	1.1%	2.9%	4.1%	5.4%	6.4%	7.1%	7.3%
DEPAKOTE	5.1%	4.5%	4.1%	3.3%	2.8%	2.5%	2.1%
DEPAKOTE-ER	7.3%	4.1%	3.1%	2.1%	1.9%	1.7%	1.5%
DILANTIN	3.5%	4.2%	3.9%	3.3%	2.5%	2.1%	1.9%
FYCOMPA						0.7%	1.1%
KEPPRA-IR	26.0%	23.7%	18.3%	16.2%	14.7%	12.5%	10.9%
KEPPRA-XR	4.8%	9.9%	10.0%	5.8%	5.2%	4.4%	4.0%
LAMICTAL	12.5%	11.2%	9.7%	8.6%	7.9%	6.5%	6.4%
LAMICTAL-XR	0.7%	4.8%	7.0%	9.6%	6.0%	4.3%	4.2%
LYRICA	3.3%	4.1%	4.4%	4.5%	5.1%	5.5%	5.5%
NEUROTONIN	0.6%	0.8%	0.7%	0.5%	0.4%	0.4%	0.3%
POTIGA				0.2%	0.5%	0.3%	0.2%
QUDEXY XR						0.0%	0.0%
SABRIL	0.1%	1.0%	1.7%	2.1%	5.4%	7.6%	9.1%
TEGRETOL	1.4%	1.7%	1.6%	1.3%	1.1%	1.0%	0.9%
TEGRETOL-XR	3.0%	2.5%	2.2%	2.1%	2.1%	2.0%	1.9%
TOPAMAX	21.1%	7.8%	6.6%	5.5%	5.0%	3.9%	3.3%
TRILEPTAL	6.5%	6.3%	6.4%	7.1%	4.2%	3.3%	3.0%
TROKENDI XR					0.1%	1.2%	1.7%
VIMPAT	2.0%	9.3%	15.0%	21.3%	27.4%	31.1%	31.9%
ZONEGRAN	1.0%	1.3%	1.3%	1.2%	1.3%	1.3%	1.3%
Total	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

**Notes:**

I understand from counsel that UCB's standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy.  
VIMPAT® launched May 2009.

**Source:**

Ex. 2176. p. 4 (IMS)

**AED U.S. Sales Dollars Associated with Epilepsy Indications**  
**2009 – February 2015**  
(\$ millions)

	2009	2010	2011	2012	2013	2014	Jan-Feb 2015
<b>Branded AED Sales</b>							
APTIOM						\$14.3	\$6.2
BANZEL	\$19.4	\$42.1	\$61.7	\$85.8	\$110.4	\$144.8	\$26.4
DEPAKOTE	\$90.8	\$65.2	\$61.4	\$51.8	\$48.3	\$50.9	\$7.5
DEPAKOTE-ER	\$128.2	\$60.6	\$46.2	\$34.2	\$32.9	\$35.0	\$5.3
DILANTIN	\$62.2	\$61.3	\$58.6	\$53.2	\$43.4	\$42.4	\$6.7
FYCOMPA						\$14.6	\$3.8
KEPPRA-IR	\$459.0	\$345.9	\$277.5	\$258.8	\$254.2	\$252.3	\$39.3
KEPPRA-XR	\$85.3	\$144.7	\$150.8	\$92.4	\$89.7	\$89.9	\$14.4
LAMICTAL	\$220.2	\$164.5	\$146.6	\$136.7	\$136.1	\$132.7	\$23.0
LAMICTAL-XR	\$13.1	\$70.0	\$106.6	\$152.6	\$104.5	\$86.8	\$15.0
LYRICA	\$57.6	\$60.5	\$66.2	\$71.1	\$88.7	\$111.4	\$19.8
NEURONIN	\$10.9	\$11.2	\$10.9	\$7.5	\$7.0	\$7.1	\$1.2
POTIGA				\$3.8	\$8.9	\$5.4	\$0.8
QUDEXY XR						\$0.0	\$0.2
SABRIL	\$1.2	\$15.2	\$25.7	\$32.8	\$93.6	\$153.7	\$32.7
TEGRETOL	\$24.1	\$24.2	\$23.5	\$20.3	\$18.4	\$19.7	\$3.2
TEGRETOL-XR	\$52.8	\$36.4	\$33.6	\$32.7	\$37.1	\$39.9	\$6.9
TOPAMAX	\$373.5	\$113.5	\$100.0	\$87.9	\$86.0	\$79.6	\$11.9
TRILEPTAL	\$115.2	\$92.3	\$97.5	\$113.3	\$73.6	\$67.5	\$10.7
TROKENDI XR					\$2.4	\$23.4	\$6.2
VIMPAT	\$35.5	\$135.8	\$227.5	\$338.6	\$475.2	\$629.0	\$114.9
ZONEGRAN	\$18.0	\$19.1	\$20.0	\$19.4	\$21.8	\$25.4	\$4.6
<b>Generic AED Sales</b>							
Generic DEPAKOTE	\$38.7	\$50.0	\$52.8	\$35.6	\$36.1	\$42.4	\$8.3
Generic DEPAKOTE-ER	\$83.2	\$38.3	\$26.1	\$22.0	\$90.8	\$132.2	\$17.4
Generic DILANTIN	\$76.0	\$67.6	\$62.7	\$48.1	\$48.6	\$59.2	\$12.0
Generic KEPPRA-IR	\$155.9	\$155.9	\$171.2	\$169.4	\$163.8	\$157.5	\$24.8
Generic KEPPRA-XR			\$4.5	\$12.7	\$15.4	\$17.4	\$2.4
Generic LAMICTAL	\$36.5	\$13.0	\$13.1	\$10.8	\$11.3	\$12.0	\$1.8
Generic LAMICTAL-XR					\$86.6	\$82.6	\$12.9
Generic NEURONIN	\$14.5	\$16.7	\$20.8	\$19.1	\$17.6	\$17.3	\$2.8
Generic TEGRETOL	\$15.2	\$14.6	\$16.1	\$16.2	\$16.8	\$49.4	\$13.1
Generic TEGRETOL-XR	\$82.8	\$99.3	\$99.4	\$95.2	\$103.3	\$102.4	\$15.4
Generic TOPAMAX	\$28.1	\$13.7	\$12.1	\$11.3	\$10.5	\$10.4	\$1.4
Generic TOPIRAMATE ER						\$0.2	\$0.2
Generic TRILEPTAL	\$44.4	\$47.3	\$39.9	\$32.0	\$42.4	\$43.7	\$6.8
Generic ZONEGRAN	\$12.1	\$12.6	\$10.8	\$9.2	\$20.9	\$17.1	\$2.2
<b>Total Sales</b>							
Total Branded	\$1,766.9	\$1,462.4	\$1,514.4	\$1,592.9	\$1,732.2	\$2,025.7	\$360.8
Total Generic	\$587.4	\$529.1	\$529.5	\$481.7	\$664.0	\$744.0	\$121.6
<b>Grand Total</b>	<b>\$2,354.2</b>	<b>\$1,991.5</b>	<b>\$2,043.9</b>	<b>\$2,074.6</b>	<b>\$2,396.2</b>	<b>\$2,769.6</b>	<b>\$482.4</b>
<b>Share of Sales</b>							
Branded AEDs	75%	73%	74%	77%	72%	73%	75%
Generic AEDs	25%	27%	26%	23%	28%	27%	25%

**Notes:**

I understand from counsel that UCB's standard business practice for evaluating the performance of VIMPAT® in the AED marketplace is to "factor" sales information related to certain AEDs to determine dollar sales that are associated with epilepsy. VIMPAT® launched May 2009.

**Source:**

Ex. 2136 (IMS)